Policy Tradeoffs: Innovation, Price Controls and Patient Access

Across global health systems, policymakers face a familiar but increasingly urgent challenge: managing rising health care costs without undermining the innovation and intellectual property systems that make future therapies possible.

Biopharmaceutical research is inherently long term. It requires substantial upfront investment and a stable intellectual property (IP) framework to ensure that successful products generate returns. When this balance is disrupted, the resulting ripple effects can slow scientific progress and delay or derail therapies patients rely on.

As debates around price controls intensify, they are often framed as a choice between affordability and innovation. In reality, both priorities must operate together.

Today’s policy decisions affect not only which medicines patients can access now, but also the scientific opportunities researchers and companies pursue in the years ahead.

International Reference Pricing and MFN

Policies such as international reference pricing or most favored nation (MFN) models may appear to offer near‑term predictability or improved affordability, but they also pose risks to the innovation ecosystem.

Europe’s experience illustrates this tension. Stringent price controls and slower market access have contributed to declining biomedical investment and reduced focus on higher‑risk, cutting‑edge research. Over time, these pressures can diminish the development of transformative therapies, particularly in areas with greater scientific uncertainty.

These lessons matter for U.S. competitiveness, especially as global rivals, including China, expand their biopharmaceutical capabilities.

During a recent hearing, the Select Committee on the CCP warned that China’s accelerating dominance across key pharmaceutical supply chains underscores how fragile the U.S. innovation ecosystem has become. Rep. Nathaniel Moran (R‑TX) emphasized that “the United States has historically led the world in medical innovation. And that leadership didn’t happen by accident.” He noted that America’s progress was built on a national commitment to scientific inquiry, strong IP protections, and respect for patients who participate in research.

But the landscape is shifting quickly, as China has made biotechnology and pharmaceuticals a strategic national priority with the clear ambition to compete with, and ultimately surpass, U.S. firms.

A recent U.S. Chamber of Commerce index adds to these concerns, finding that proposals to apply MFN pricing and expand the use of march‑in rights are creating uncertainty for investors and researchers, potentially weakening the environment needed for high‑risk biomedical R&D.

The Innovation Equation

From discovery to approval, developing new medicines requires years of research, substantial capital and tolerance for failure. Early‑stage companies in particular rely on confidence in the future value of their discoveries.

Strict or uneven price ceilings can shift which diseases are prioritized, how research is funded and where clinical trials or product launches occur. These effects accumulate, reshaping the pipeline long after policies are implemented.

Designing Policy with Intention

As highlighted by the U.S. Chamber of Commerce index, strong and predictable intellectual property frameworks such as Bayh‑Dole remain essential to scientific progress and technology transfer. As policymakers weigh new pricing or licensing changes, preserving the stability of these structures is critical to maintaining America’s leadership in biomedical innovation.

A durable policy path balances near‑term affordability with the incentives that enable long‑term scientific advancement.

The goal is to safeguard today’s patient access and tomorrow’s breakthroughs.